Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2 | Zendy

Shinichiro Uchiyama | Zendy; Yukito Shinohara | Zendy; Yasuo Katayama | Zendy; Takenori Yamaguchi | Zendy; Shunnosuke Handa | Zendy; Kempei Matsuoka | Zendy; Yasuo Ohashi | Zendy; Norio Tanahashi | Zendy; Hiroko Yamamoto | Zendy; Chokoh Genka | Zendy; Yasuhisa Kitagawa | Zendy; Hideo Kusuoka | Zendy; K Nishimaru | Zendy; Motoo Tsushima | Zendy; Yukihiro Koretsune | Zendy; Tohru Sawada | Zendy; Chikuma Hamada | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2

Author(s) -

Shinichiro Uchiyama,

Yukito Shinohara,

Yasuo Katayama,

Takenori Yamaguchi,

Shunnosuke Handa,

Kempei Matsuoka,

Yasuo Ohashi,

Norio Tanahashi,

Hiroko Yamamoto,

Chokoh Genka,

Yasuhisa Kitagawa,

Hideo Kusuoka,

K Nishimaru,

Motoo Tsushima,

Yukihiro Koretsune,

Tohru Sawada,

Chikuma Hamada

Publication year - 2014

Publication title -

cerebrovascular diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.221

H-Index - 104

eISSN - 1421-9786

pISSN - 1015-9770

DOI - 10.1159/000360811

Subject(s) - medicine , cilostazol , stroke (engine) , aspirin , hazard ratio , incidence (geometry) , confidence interval , proportional hazards model , cumulative incidence , lacunar stroke , cardiology , cohort , ischemic stroke , ischemia , mechanical engineering , physics , optics , engineering

The Cilostazol Stroke Prevention Study 2 (CSPS 2) showed that cilostazol significantly reduced the risk of stroke by 25.7% relative to aspirin, with significantly fewer hemorrhagic events, in patients with prior ischemic stroke, excluding cardioembolic stroke. However, whether the benefit of cilostazol is sustained in patients with a high risk of bleeding has not been examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research